title: A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses.
abstract: Antipsychotics can induce in schizophrenic (SZ) and bipolar disorder (BP) patients serious body weight changes that increase risk for noncompliance to medication, and risk for cardiovascular diseases and diabetes. A genetic origin for this susceptibility to weight changes has been hypothesized because only a proportion of treated patients are affected, the degree of affection differing also in rates and magnitudes. In a first genome scan on obesity under antipsychotics in SZ and BP, we analyzed 21 multigenerational kindreds (508 family members) including several patients treated for a minimum of 3 years mainly with haloperidol or chlopromazine. Obesity was defined from medical files and was shown to be 2.5 times more frequent in patients treated with antipsychotics than in untreated family members (30 vs 12%). The nine pedigrees that showed at least two occurrences of obesity under antipsychotics were submitted to model-based linkage analyses. We observed a suggestive linkage with a multipoint Lod score (MLS) of 2.74 at 12q24. This linkage finding vanished when we used as phenotypes, obesity unrelated to antipsychotics, and when we used SZ or BP. This suggests that this positive linkage result with obesity is specific to the use of antipsychotics. A potential candidate gene for this linkage is the pro-melanin-concentrating hormone (PMCH) gene located at less then 1 cM of the linkage. PMCH encodes a neuropeptide involved in the control of food intake, energy expenditure, and in anxiety/depression. This first genome scan targeting the obesity side effect of antipsychotics identified 12q24 as a susceptibility region.
authors.affiliation: Laval University Research Center Robert-Giffard, Beauport, Québec G1J 2B3, Canada. yvon.chagnon@crulrg.ulaval.ca
authors.forename: Y C
authors.initials: YC
authors.lastname: Chagnon
authors.forename: C
authors.initials: C
authors.lastname: Mérette
authors.forename: R H
authors.initials: RH
authors.lastname: Bouchard
authors.forename: C
authors.initials: C
authors.lastname: Emond
authors.forename: M-A
authors.initials: MA
authors.lastname: Roy
authors.forename: M
authors.initials: M
authors.lastname: Maziade
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D001714:Bipolar Disorder / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*; D002746:Chlorpromazine / Q000009:adverse effects; D002881:Chromosomes, Human, Pair 12 / Q000235:genetics; D015897:Comorbidity; D008040:Genetic Linkage; D020022:Genetic Predisposition to Disease; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D007028:Hypothalamic Hormones / Q000235:genetics; D008126:Lod Score; D008957:Models, Genetic; D009765:Obesity / Q000139:chemically induced / Q000453:epidemiology / Q000235:genetics*; D010375:Pedigree; D011498:Protein Precursors / Q000235:genetics; D011618:Psychotic Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics; D011792:Quebec / Q000453:epidemiology; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics*
chemical_list: D014150:Antipsychotic Agents; D007028:Hypothalamic Hormones; D011498:Protein Precursors; C059991:melanin-concentrating hormone precursors; D006220:Haloperidol; D002746:Chlorpromazine